The Small Intestine Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Small Intestine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Small Intestine Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Small Intestine Cancer and features dormant and discontinued products.
GlobalData tracks 24 drugs in development for Small Intestine Cancer by 24 companies/universities/institutes. The top development phase for Small Intestine Cancer is phase ii with 15 drugs in that stage. The Small Intestine Cancer pipeline has 23 drugs in development by companies and one by universities/ institutes. Some of the companies in the Small Intestine Cancer pipeline products market are: Novartis, Osaka University and Merck.
The key targets in the Small Intestine Cancer pipeline products market include Programmed Cell Death Protein 1, GTPase KRas, and Fibroblast Growth Factor Receptor 4.
The key mechanisms of action in the Small Intestine Cancer pipeline product include Programmed Cell Death Protein 1 Antagonist with four drugs in Phase II. The Small Intestine Cancer pipeline products include 14 routes of administration with the top ROA being Oral and eight key molecule types in the Small Intestine Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Small Intestine Cancer overview
Small intestine cancer, a rare malignancy, originates when malignant cells form in the tissues of the small intestine. This vital organ, composed of diverse cell types, gives rise to various cancer types. Adenocarcinomas, arising from gland cells lining the intestine, constitute approximately one-third of small intestine cancers. Carcinoid tumors, a subtype of neuroendocrine tumors, are generally slow-growing and the most prevalent small intestine tumors. Lymphomas, originating in lymphocytes, can manifest in the small intestine, while sarcomas, starting in connective tissues like muscle, include gastrointestinal stromal tumors (GISTs). Understanding these distinct types is crucial for accurate diagnosis and tailored treatment approaches.
For a complete picture of Small Intestine Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
